CLGN Stock Analysis: Buy, Sell, or Hold?
CLGN - CollPlant Biotechnologies Ltd Ordinary Shares
$0.34
0.00 (0.03%)
▲
5d:
+0.93%
30d:
-19.72%
90d:
-44.74%
BUY
MODERATE Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: May 27, 2026
0d
Get Alerted When CLGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CLGN shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CLGN shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CLGN is currently trading at $0.34, which is considered oversold relative to its 30-day fair value range of $0.35 to $0.43. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.9) compared to its historical average (3.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CLGN is in a downtrend. Immediate support is located at $0.30, while resistance sits at $0.42.
Market Sentiment: CLGN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.12 (+3198.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CLGN is in a downtrend. Immediate support is located at $0.30, while resistance sits at $0.42.
Market Sentiment: CLGN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.12 (+3198.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.35 -
$0.43
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 3198.7% below Wall St target ($11.12)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$0.35 -
$0.43
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.31
Resistance Level
$0.42
Current Trend
Downtrend
Technical data as of
Jun 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.87
Wall Street Target
$11.12
(+3198.7%)
Revenue Growth (YoY)
-96.4%
PE vs Historical
-1.9 vs 3.5
CHEAP
Share & Embed Analysis
Last updated: June 22, 2026 7:02 AM ET
Data refreshes hourly during market hours. Next update: 8:02 AM
Data refreshes hourly during market hours. Next update: 8:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 57 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 52 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 57 HOLD |
